Want to see DE:V3V full AI Analyst Report?
Top Page
VITA 34
(XETRA:V3V)
Select Model
Select Model
Rating:46Neutral
Price Target:
€3.00
▲(4.90% Upside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by improving operating performance and positive TTM cash generation, but is constrained by a riskier balance sheet (thin equity and higher leverage) and a still-loss-making bottom line. Technically, the stock remains in a broader downtrend versus key moving averages, and valuation signals are weak due to the negative P/E.
Positive Factors
Recurring biobanking revenue
The combination of upfront processing income and recurring storage fees gives VITA 34 a more durable revenue base than a purely transactional service. Active contracts can continue generating fees over many years, supporting customer retention, revenue visibility, and operating planning.
Negative Factors
Ongoing net losses
Persistent operating and net losses weaken earnings quality and limit the company’s ability to build equity through retained profits. Until profitability improves, cash generation may not translate into durable earnings strength, leaving the business more exposed to execution setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring biobanking revenue
The combination of upfront processing income and recurring storage fees gives VITA 34 a more durable revenue base than a purely transactional service. Active contracts can continue generating fees over many years, supporting customer retention, revenue visibility, and operating planning.
Read all positive factors
VITA 34 (V3V) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€51.25M
Dividend Yield1.14%
Average Volume (3M)1.10K
Price to Earnings (P/E)―
Beta (1Y)0.13
Revenue Growth0.06%
EPS Growth22.85%
CountryDE
Employees723
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.43
Shares Outstanding17,640,104
10 Day Avg. Volume669
30 Day Avg. Volume1,098
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)14.70
Price to Sales (P/S)1.19
P/FCF Ratio-420.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)€85.00M
VITA 34 Business Overview & Revenue Model
Company Description
VITA 34 AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced ther...
How the Company Makes Money
VITA 34 makes money primarily by providing fee-based biobanking services for newborn stem cells. Its core revenue model is built on (1) up-front service fees charged for the collection kit, logistics, laboratory processing/testing, and initial cry...
VITA 34 Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
34
Negative
Cash Flow
52
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 87.78M | 88.17M | 82.18M | 77.06M | 68.94M | 28.42M |
| Gross Profit | 54.13M | 44.84M | 20.65M | 28.24M | 2.73M | 12.44M |
| EBITDA | 5.65M | 4.76M | -443.00K | 5.81M | -18.34M | 949.00K |
| Net Income | -7.67M | -6.30M | -12.14M | -1.86M | -27.39M | -3.93M |
Balance Sheet | ||||||
| Total Assets | 162.35M | 168.26M | 152.74M | 158.36M | 151.51M | 177.95M |
| Cash, Cash Equivalents and Short-Term Investments | 12.45M | 11.88M | 18.46M | 17.42M | 18.23M | 35.26M |
| Total Debt | 23.03M | 23.51M | 18.10M | 21.57M | 28.18M | 32.32M |
| Total Liabilities | 158.45M | 162.84M | 139.83M | 135.58M | 135.66M | 136.00M |
| Stockholders Equity | 5.05M | 7.12M | 14.13M | 23.56M | 16.50M | 43.07M |
Cash Flow | ||||||
| Free Cash Flow | 4.32M | -249.00K | 5.46M | 5.06M | -10.92M | 467.00K |
| Operating Cash Flow | 7.14M | 3.88M | 8.65M | 9.15M | -4.49M | 2.73M |
| Investing Cash Flow | -7.82M | -12.66M | -3.08M | -3.57M | -5.81M | 24.87M |
| Financing Cash Flow | 1.61M | 3.89M | -6.09M | -5.09M | -6.27M | -4.70M |
VITA 34 Technical Analysis
Neutral
2.86
Price Trends
2.98
Negative
3.52
Negative
4.43
Negative
Market Momentum
>-0.01
Negative
52.65
Neutral
60.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:V3V, the sentiment is Neutral. The current price of 2.86 is above the 20-day moving average (MA) of 2.86, below the 50-day MA of 2.98, and below the 200-day MA of 4.43, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.65 is Neutral, neither overbought nor oversold. The STOCH value of 60.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:V3V.
VITA 34 Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | €261.25M | 9.05 | 11.54% | 0.73% | 2.94% | -14.28% | |
60 Neutral | €293.57M | -603.75 | -0.17% | 2.44% | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | €275.97M | 24.59 | 2.16% | ― | 9.88% | -38.44% | |
46 Neutral | €51.25M | -6.78 | -94.93% | 1.14% | 0.06% | 22.85% |
* General Sector Average
DE:V3V
VITA 34
2.94
-3.96
-57.39%
DE:MED
MEDICLIN
5.50
2.53
85.31%
DE:SBS
STRATEC Biomedical
24.55
-1.02
-3.97%
DE:ILM1
Medios AG
10.84
-3.90
-26.46%
DE:HAEK
HAEMATO AG
12.70
2.03
19.07%
DE:7V0
Novogenia Holding AG
7.40
1.57
26.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.